Pronutria Biosciences, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2022 | $6 M | No. 3 | $2 to $10 million | debt, options | SEC | |
| Feb 2016 | $43 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jan 2015 | $44 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pronutria Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2022).
SEC Form D · Sep 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2022
That is all the official record says: Pronutria Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Flagship VentureLabs IV, LLC | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Flagship Ventures 2007 General Partner LLC | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Flagship Ventures Fund 2007, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Flagship Ventures Fund IV General Partner LLC | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Flagship Ventures Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Flagship Ventures Fund IV-Rx, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Flagship Ventures Opportunities Fund I General Partner LLC | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Flagship Ventures Opportunities Fund I, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 12 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Margaret Koziel | Executive officer | Sep 2022 |
| Paul Fehlner | Executive officer | Sep 2022 |
| Robert Crane | Executive officer | Sep 2022 |
| Virginia Dean | Executive officer | Sep 2022 |
| William Hinshaw | Executive officer | Sep 2022 |
| Jeff Barton Moore | Executive officer | Feb 2017 |
| Robert Connelly | Executive officer | Feb 2017 |
| Garry Barton Menzel | Executive officer | Feb 2016 |
| Catherine A. Sohn | Director | Sep 2022 |
| Cristina M. Rondinone | Director | Sep 2022 |
| David R. Epstein | Director | Sep 2022 |
| Gary D. Pisano | Director | Sep 2022 |
| Martin D. Hendrix | Director | Sep 2022 |
| Michael D. Rosenblatt | Director | Sep 2022 |
| Paul D. Sekhri | Director | Sep 2022 |
| William D. Baird | Director | Sep 2022 |
| William Hinshaw | Director | Sep 2022 |
| Charles Cooney | Director | Feb 2017 |
| Chris Barton Viehbacher | Director | Feb 2017 |
| David Berry | Director | Feb 2017 |
| Gary Barton Pisano | Director | Feb 2017 |
| Gregory Behar | Director | Feb 2017 |
| John Barton Mendlein | Director | Feb 2017 |
| Noubar Afeyan | Director | Feb 2017 |
| Peter Barton Hutt | Director | Feb 2017 |
| Robert Connelly | Director | Feb 2017 |
| Stephen Hoge | Director | Feb 2017 |
| Glenn Barton Nedwin | Director | May 2015 |
About
Company in Cambridge, United States.